Cigna (CI) Stock Forecast & Price Target

Cigna Group is well positioned fundamentally because its earnings base is increasingly anchored by higher-quality, non-government businesses in Evernorth and employer-sponsored health benefits, with Specialty & Care and Pharmacy Benefits providing scale, diversification, and a favorable mix shift toward specialty drug capabilities. The recent 1Q26 results support that view, as management delivered EPS upside driven by Specialty & Care core strength and Healthcare MLR improvement, while PBM pressure appears transitory given the ~28% decline was burdened by about $150 million of headwinds and should decelerate as absolute PBM AOI grows. With roughly 18 million total members, about 60% of earnings coming from Evernorth, a successful multiyear Centene win, and an AI risk-prediction model already generating about $2,000 in annual savings per engaged member, the company shows both operating momentum and clear evidence that its core businesses can compound value over time.

Cigna Group is facing a fundamentally mixed but ultimately negative setup because its earnings quality depends heavily on Evernorth and specialty pharmacy execution while core risks remain concentrated in healthcare cost trend mispricing, rebate-model margin erosion, and client loss or outmigration that could blunt growth. Although the company has benefited from specialty outperformance, biosimilar mix shifts, and stronger retention in the 2027 Pharmacy Benefit selling season, those positives may not be enough to offset structural pressure from a turbulent managed care backdrop, especially if U.S. unemployment rises and commercial membership weakens. Even with reported 16 million US and 2 million international medical members as of December 2025 and the added scale from the 2018 merger with Express Scripts, the business still appears vulnerable to margin compression and uneven demand across its mostly US-based insurance and PBM platforms.